HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

Key Points

• HC Wainwright has revised its earnings per share estimate for Zevra Therapeutics for FY2027 from $1.92 to $1.78, while maintaining a "Buy" rating and a price target of $26.00.
• During its latest earnings report, Zevra Therapeutics missed analysts' expectations with an EPS of ($0.06) compared to the estimated $1.43, despite revenues of $25.88 million exceeding expectations.
• Shares of Zevra Therapeutics have experienced a drop of 8.1%, with recent trades highlighting a price of $8.67 per share.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $1.78 per share for the year, down from their prior forecast of $1.92. HC Wainwright has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' FY2029 earnings at $3.45 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($1.49). Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 149.99%. The business had revenue of $25.88 million during the quarter, compared to the consensus estimate of $22.49 million.

A number of other equities analysts have also commented on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday. JMP Securities decreased their price objective on Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating for the company in a report on Wednesday. Cantor Fitzgerald boosted their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. Finally, Wall Street Zen downgraded Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Trading Down 8.1%

Shares of NASDAQ:ZVRA traded down $0.77 during midday trading on Thursday, hitting $8.67. 1,643,260 shares of the stock were exchanged, compared to its average volume of 701,565. The stock has a market capitalization of $473.80 million, a price-to-earnings ratio of -41.54 and a beta of 1.87. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The business's 50-day moving average price is $10.55 and its 200 day moving average price is $8.74. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its holdings in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company's stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares in the last quarter. Invesco Ltd. lifted its holdings in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after purchasing an additional 3,007 shares in the last quarter. Carret Asset Management LLC lifted its holdings in Zevra Therapeutics by 9.7% during the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company's stock worth $349,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock worth $1,148,000 after purchasing an additional 3,827 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.